Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians

Int J Chron Obstruct Pulmon Dis. 2017 Mar 22:12:803-812. doi: 10.2147/COPD.S114423. eCollection 2017.

Abstract

Airway mucus hypersecretion is a frequent symptom associated with acute and chronic airway disease. Inhibition of mucus production or promotion of mucolysis not only relieved symptoms but also improved disease outcomes. There are numerous available mucoactive medicines for prescription, and how to select them properly for different diseases is important for clinical practice. So far, there is no one consensus or guideline reported. A group of Chinese pulmonary physicians worked together to complete this consensus based on literature review, summarized mechanism and usage of each classical mucoactive medicine. In general, antioxidant mucoactive medicines play an important role in chronic airway disease, including but not limited to airway mucus clearance, reduced acute exacerbation and improved pulmonary function.

Keywords: chronic bronchitis; mucolysis; sputum.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Antioxidants / adverse effects
  • Antioxidants / therapeutic use*
  • China
  • Consensus
  • Disease Progression
  • Expectorants / adverse effects
  • Expectorants / therapeutic use*
  • Humans
  • Lung / drug effects*
  • Lung / metabolism
  • Lung / physiopathology
  • Mucociliary Clearance / drug effects*
  • Mucus / metabolism*
  • Pulmonary Disease, Chronic Obstructive / diagnosis
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Pulmonologists*
  • Quality of Life
  • Recovery of Function
  • Treatment Outcome

Substances

  • Antioxidants
  • Expectorants